Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Cheng

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|April 14, 2015
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 StudyAnthony Mills, Gordon Crofoot, Cheryl McDonald, et al.
Vaccines|July 8, 2020
Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 ExposureLilin Lai, Kevin Ault, Nadine Rouphael, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 ResultsDavid Wohl, Shinichi Oka, Nathan Clumeck, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 4, 2020
Assessing non-Mendelian inheritance in inherited axonopathiesDana M Bis-Brewer, Ziv Gan-Or, Patrick Sleiman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.
The Lancet. Gastroenterology & Hepatology|October 6, 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Juan P Frias, Guy Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 10, 2023
Influenza Vaccine Effectiveness Pre-pandemic Among Adults Hospitalized With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease and Older AdultsAshley Tippett, Gabby Ess, Laila Hussaini, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Journal of Acquired Immune Deficiency Syndromes (1999)|April 14, 2015
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 StudyAnthony Mills, Gordon Crofoot, Cheryl McDonald, et al.
Vaccines|July 8, 2020
Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 ExposureLilin Lai, Kevin Ault, Nadine Rouphael, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 ResultsDavid Wohl, Shinichi Oka, Nathan Clumeck, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 4, 2020
Assessing non-Mendelian inheritance in inherited axonopathiesDana M Bis-Brewer, Ziv Gan-Or, Patrick Sleiman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.
The Lancet. Gastroenterology & Hepatology|October 6, 2023
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialStephen A Harrison, Juan P Frias, Guy Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 10, 2023
Influenza Vaccine Effectiveness Pre-pandemic Among Adults Hospitalized With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease and Older AdultsAshley Tippett, Gabby Ess, Laila Hussaini, et al.
Pageof 12